The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Trimetazidine (Primary)
- Indications Angina pectoris; Coronary artery disease
- Focus Therapeutic Use
- Acronyms PATMOS
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 07 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.